Form 4: Kenvue CSO Receives 63,525 RSU Grant

Kenvue's Chief Scientific Officer, Caroline Tillett, was granted 63,525 Restricted Stock Units, aligning her interests with long-term shareholder value.

Summary

• Caroline Tillett, Chief Scientific Officer of Kenvue Inc., was granted 63,525 Restricted Stock Units (RSUs).
• The transaction date for this grant was March 2, 2026.
• Each RSU corresponds one-for-one with the Company's common stock.
• The award vests in three equal installments on March 2, 2027, March 2, 2028, and March 2, 2029.
• Vesting is contingent upon Ms. Tillett's continued service through each respective vesting date.
• Following this transaction, Ms. Tillett beneficially owns 63,525 derivative securities (RSUs) directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive commitment and aligns management incentives with long-term shareholder value, which is generally favorable for investors.

Positives

• The grant of Restricted Stock Units aligns the Chief Scientific Officer's interests with the long-term performance of Kenvue Inc.
• The multi-year vesting schedule encourages executive retention and sustained focus on company growth.

Negatives

• The Restricted Stock Units do not provide immediate liquidity or cash value to the executive until they vest and convert to common stock.
• The value of the award is subject to the future market price of Kenvue's common stock.

Risks

• The vesting of the Restricted Stock Units is subject to the reporting person's continued service through the specified vesting dates.
• The ultimate value realized from the RSUs depends on the future performance and market price of Kenvue's common stock.

Future Outlook

The grant of Restricted Stock Units to the Chief Scientific Officer indicates a long-term commitment from key management and is designed to incentivize sustained performance and retention through the multi-year vesting schedule.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units is a standard practice in the consumer health and pharmaceutical industries for executive compensation. This method aligns executive incentives with long-term shareholder value and is commonly used by peers to retain top talent and encourage sustained performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a widely adopted practice across global industries, including consumer goods and healthcare, similar to companies like Procter & Gamble (PG), Johnson & Johnson (JNJ), and Unilever (UL).
• The multi-year vesting schedule (three equal installments) is a common structure designed to promote long-term executive retention and performance, consistent with compensation strategies observed in leading multinational corporations.
• A grant price of $0 for RSUs is standard, as these awards represent a future equity stake contingent on service, rather than an immediate purchase.

Related Party Transactions

• Grant of 63,525 Restricted Stock Units to Caroline Tillett, Chief Scientific Officer, as part of her executive compensation package.

Stakeholder Impact

• Shareholders: Positive impact through enhanced alignment of executive interests with long-term company performance and shareholder value creation.
• Employees: May signal stability in executive leadership and a commitment to long-term strategic goals.

Next Steps

• First RSU vesting on March 2, 2027.
• Second RSU vesting on March 2, 2028.
• Third RSU vesting on March 2, 2029.

Key Dates

Recommendation

The grant of Restricted Stock Units to a key executive is a routine compensation event that aligns management's interests with long-term shareholder value but does not fundamentally alter the company's immediate financial prospects or warrant a change in investment recommendation based solely on this filing. Investors should continue to monitor Kenvue's broader financial performance and strategic initiatives.

Keywords

Kenvue, KVUE, Restricted Stock Units, RSU, Insider Transaction, Form 4, Executive Compensation, Caroline Tillett, Equity Grant